Osivax

Influenza Vaccination

Clinical research in influenza centers on preventive vaccines designed to reduce type A influenza illness in healthy adults. The sponsor’s studies focus on immunogenicity, efficacy, and safety in the context of seasonal respiratory infection.

  • Influenza vaccine development
  • Type A influenza prevention
  • Respiratory viral disease protection

The work reflects interest in adult vaccination strategies and immune protection against laboratory-confirmed influenza illness.

Sarbecovirus Vaccines

Research activity also includes sarbecovirus vaccine development, with attention to candidate vaccines intended to support protection against coronavirus threats. The clinical focus includes safety, reactogenicity, and immune response assessment in adults.

  • Sarbecovirus candidate vaccines
  • Coronavirus immunisation
  • Adult vaccine safety

These studies place emphasis on intramuscular vaccination and the evaluation of immune activity relevant to broad coronavirus coverage.

Cell-mediated Immunity and Immunogenicity

The sponsor’s trial portfolio includes detailed assessment of cell-mediated immune responses, with measurement of antigen-specific T-cell activity and broader immunogenicity outcomes after vaccination. These endpoints are central to understanding vaccine-induced protection in adult participants.

  • T-cell response evaluation
  • Antigen-specific immune responses
  • Vaccine immunogenicity

Such work supports the clinical development of vaccines aimed at generating measurable adaptive immune responses.

Preventive Infectious Disease Research

Across its active studies, the sponsor is engaged in preventive infectious disease research in healthy adults, with a therapeutic interest in respiratory pathogens and vaccine-based disease prevention. The portfolio spans both influenza and coronavirus targets.

  • Adult preventive vaccination
  • Respiratory infection prevention
  • Healthy volunteer studies

Clinical activity is concentrated on vaccine candidates intended for infectious disease prevention rather than treatment.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Safety and Immune Response of OVX033 Vaccine for Adults with Sarbecovirus Disease

    Not yet recruiting

    1 1
    Investigated drugs:
    France
  • Study on the Effectiveness and Safety of OVX836 Vaccine for Preventing Influenza in Healthy Adults Aged 18-59

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Finland France Germany